Management of Prostate Cancer in Central China

Prostate Cancer Clinical Trial

Official title:

Comparisons of Management and Outcome of Prostate Cancer in Central China Between 2003 and 2008: A Multi-institutional Report

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01614548
• Other study ID #: ZZU2012
• Status: Completed
• Phase: N/A
• First received: June 2, 2012
• Last updated: June 5, 2012
• Start date: January 2003
• Est. completion date: December 2011

Study information

• Verified date: June 2012
• Source: Zhengzhou University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Some recent reports indicate that incidence of prostate cancer is increasing rapidly in China. However, no large-scale survey of prostate cancer has been done in central China, few data are available regarding its management. The investigators aimed to analyze the management of prostate cancer and compare the outcome of patients with such a survey.

The investigators collected data of patients diagnosed with prostate cancer from the 2003 and 2008 in central China. Data were disaggregated by rural and urban hukou. The survival rate of patients was analyzed using Kaplan-Meier method. Prognostic factors were analyzed using the log-rank test and Cox proportional hazards model.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 789
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients with newly diagnosed prostate cancer were included in the study. Exclusion Criteria:

• Those with a history of prostate cancer who were treated for another disease were excluded from study.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
China	the first affiliated hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (13)

Lead Sponsor

Collaborator

Zhengzhou University

Anyang Regional Hospital, Center hospital of Nanyang, Center hospital of Shangqiu, Center hospital of Zhumadian, First People's Hospital of Kaifeng, Luoyang Central Hospital, People's Hospital of Zhengzhou University, the cancer hospital of Zhengzhou University, The First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Zhengzhou University, Xinyang Central Hospital, Zhoukou Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	overall survival that was defined as the interval from the date of diagnosis to the Medicare date of death	3 years